Transgene
Blood & Organ Banks · France · 51-200 Employees
View Company Info for Free
Overview
Headquarters
D'andernach Parc D'innovation Cs80166 40...Phone Number
+33 388279100Website
www.transgene.frRevenue
<$5 MillionStock Symbol
TNGIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
2
3
3
2
About Transgene
Transgene specializes in the design and development of innovative immunotherapies for cancer treatment. Their product portfolio includes personalized therapeutic vaccines like TG4050, oncolytic viruses from the Invir.IO platform, and advanced technologies such as myvac. The company aims to leverage cutting-edge genetic engineering and artificial intelligence to enhance cancer treatment efficacy. Transgene targets patients with various types of cancer, focusing on personalized medicine to improve patient outcomes.Explore more
Transgene Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Transgene your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Transgene had a recent Job posting/layoffs
Earning: See what the market has to say on Transgene recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Transgene
Check if Transgene has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Transgene launches new products
Check out if Transgene is spiking on competitors!
Transgene, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Transgene has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Transgene is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Transgene is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Transgene.
Transgene financials insights
Gather financial insights about Transgene, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Debt
$22.4M
2025
Stock/Share Issuance
$121.6M
Transgene Tech Stack
A closer look at the technologies used by Transgene
See more technologies
Most Recent Scoops
Project
Transgene is transitioning its MVA manufacturing process from a chicken embryo fibroblast (CEF) process to a scalable avian cell line process, offering improved robustness, shorter turnaround time, easier industrialization and automation, and scalability, with no impact on existing clinical data.
Research & Development, Manufacturing Operations
Project
Transgene has presented preclinical data at the World Congress on Infectious Diseases in Barcelona demonstrating that TG-MVA produced on cell line shows comparable efficacy, immunogenicity, and safety to the Bavarian Nordic reference vaccine, and is planning a randomized trial in healthy volunteers to further evaluate the cell line-produced vaccine.
Medical Research, Clinical Operations
Project
Transgene has announced that its individualized neoantigen therapeutic vaccine platform is expandable to additional oncology indications, including gastric cancer, triple-negative breast cancer, bladder cancer, and other tumor types with significant relapse risk in early-stage settings.
Medical Research, Pharmaceuticals
Project
Transgene has reported that TG4050 demonstrated 100% disease-free survival at 2 years, with 73% of patients showing an immune response to neoantigens, durable immunogenicity at 12 months post-therapy, and a favorable safety profile.
Medical Research
Project
Pharmaceuticals
Transgene News & Media
Transgene to Present Preclinical Data Demonstrating Robust Protection Against Mpox with its Novel Scalable Cell Line–Derived MVA Vaccine Candidate (TG MVA(TM)) at WCID 2026
Transgene to Present Preclinical Data Demonstrating Robust Protection Against Mpox with its Novel Scalable Cell Line–Derived MVA Vaccine Candidate at WCIDTransgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine
Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic VaccineTransgene to Present Preclinical Data on Novel TG-MVA Prophylactic Vaccine Against mpox at the World Congress on Infectious Diseases
TG-MVA builds on Transgene’s expertise in MVA (Modified Vaccinia Ankara) viral vectors, which are well established in smallpox vaccines developmentTransgene’s Combined General Meeting of May 22, 2026
Transgene’s Combined General Meeting of May 22, 2026
Read more news
Top Blood & Organ Banks Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Transgene
Sign Up For FreeTo access detailed company insights
Transgene specializes in the design and development of innovative immunotherapies for cancer treatment. Their product portfolio includes personalized therapeutic vaccines like TG4050, oncolytic viruses from the Invir.IO platform, and advanced technologies such as myvac. The company aims to leverage cutting-edge genetic engineering and artificial in... Read More
